Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, had its shares halted from trading pending an announcement.
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
Most listened to
- Fonterra chief executive Theo Spierings is confident on the outlook for farmers though challenges remain
- Business leaders on Budget 2017: One of Andy Hamilton’s "very contentious" Budget wishes is for greater regulation of "pockets of our economy"
- Phil Twyford may have said the Point England development bill is just "nuts," but Bill English thinks opposition is "just dumb"
- Budget 2017: Grant Thornton's Murray Brewer thinks the IRD's new tax software should make its work easier and more efficient
- NBR's Jenny Ruth on Forsyth Barr downgrading Steel & Tube
- NBR Radio: best of the week ended May 19, with Grant Walker